Jubilant Pharmova Reports Strong Profit Growth Amid Long-Term Challenges
Jubilant Pharmova has recently experienced an evaluation adjustment following a strong financial performance in Q3 FY24-25, marked by a significant net profit increase. The company has demonstrated operational efficiency with high ROCE and turnover ratios, although it faces challenges in long-term growth trends.
Jubilant Pharmova, a midcap player in the Pharmaceuticals & Drugs industry, has recently undergone an adjustment in its evaluation. The company reported very positive financial performance for the third quarter of FY24-25, highlighted by a notable growth in net profit of 89.49%. This marks the sixth consecutive quarter of positive results for Jubilant Pharmova, showcasing its ability to maintain a strong performance in a competitive market.Key financial metrics indicate a robust operational efficiency, with the highest recorded Return on Capital Employed (ROCE) at 8.37% and an impressive inventory turnover ratio of 5.92 times. Additionally, the debtors turnover ratio reached a peak of 8.65 times, reflecting effective management of receivables.
Despite these positive indicators, the company has faced challenges in long-term growth, with net sales and operating profit showing declines over the past five years. Furthermore, the stock's technical indicators have shifted, reflecting a change in market sentiment.
Overall, the evaluation adjustment reflects a nuanced view of Jubilant Pharmova's current standing in the market, considering both its recent performance and longer-term trends.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
